Skip to content
Biotechnology

Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

ZeptoMetrix 2 mins read

TRONDHEIM, NORWAY / ACCESSWIRE / January 17, 2024 / Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.



This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron's commitment to advancing the field of environmental analysis.

The newly inaugurated research facility, which offers a 360-degree view of the Trondheim fjord, is equipped to address the most challenging pollutants of today, including microplastics and PFAS (commonly known as ‘forever chemicals'), and is poised to contribute significant research into environmental surveillance.

This strategic relocation follows Chiron's acquisition by Antylia Scientific in July 2023 and its successful incorporation into the ZeptoMetrix® Operating Division. The move to the new 1750 m2 premises aligns Chiron with Spex®, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.

"We are excited to embark on this journey of heightened environmental surveillance," Jon Eigill Johansen, Founder of Chiron AS, commented. "The establishment of our research centre highlights our commitment to scientific excellence. Through cutting-edge research and collaboration, we aim to support our mission to protect humans from undesired chemical exposure."

Evangeline Gonzalez, President of the ZeptoMetrix Operation Division, stated, "This investment reinforces our dedication to advancing environmental science. Chiron's state-of-the-art research centre adds a crucial dimension to the ZeptoMetrix portfolio. This means we are even more ready to support our lab and industry partners with critical innovation as they work to address ongoing environmental challenges."

About ZeptoMetrix®

ZeptoMetrix, an Antylia Scientific Company, is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology Infectious Disease, Oncology market and Analytical Reference Materials for the Applied Markets. We focus on our customers' success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in stock solutions to custom control and panel development through to launch, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is an operating division of Antylia Scientific, a holding company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.

Contact Information

Jennifer Button
Deputy Director
jenny.button@chiron.no
+44(0)7963508499

Related Files

Chiron AS Establishes State-of-the-Art Research Centre.pdf

SOURCE: Chiron AS

.

View the original press release on newswire.com.

More from this category

  • Biotechnology
  • 03/10/2024
  • 11:28
Island Pharmaceuticals

Island doses Phase 2a subjects in its ISLA-101 Phase 2a/b PROTECT clinical trial; investors invited to 8 October webinar

MELBOURNE Australia, 3 October 2024: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; Island or the Company) is pleased to announce it has dosed all subjects in the Phase 2a component of its ISLA-101 Phase 2a/b clinical trial in dengue fever. The study, known as PROTECT, is a cutting edge clinical trial design that capitalises on years of research by theU.S. Army to develop an attenuated strain of the dengue virus, which can be used to examine a dengue infection in a highly controlled setting. The challenge virus causes a mild but clinically relevant dengue infection in the…

  • Biotechnology
  • 02/10/2024
  • 22:11
Recursion Pharmaceuticals, Inc.

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing of Phase 1/2 in Q4 2024 to evaluate REC-1245 in a biomarker enriched patient population, including patients with solid tumors and lymphomaSALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug (IND) application for a Phase 1/2 clinical trial of REC-1245, a new…

  • Biotechnology
  • 01/10/2024
  • 08:14
Cartherics Pty Ltd

CARTHERICS RAISES OVER $15 MILLION IN OVERSUBSCRIBED PRIVATE FINANCING ROUND TO ADVANCE CELL THERAPY PROGRAMS

Financing round was significantly oversubscribed by existing investors and new private investors. Funding will enable the Company to progress clinical trials of its lead CAR-NK cell therapy product, CTH-401, in ovarian cancer and expand its pipeline to additional disease indications. Melbourne, Australia, 1 October 2024 – Cartherics Pty Ltd(“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, is pleased to announce that it has successfully raised well over its target AU$15M in an oversubscribed financing round. This funding will support the initiation of the clinical trial for CTH-401, the Company’s lead cell…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.